– USA, FL – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease, announced the appointment of Adele Gulfo to its Board as an independent director.
About Adele Gulfo
Adele Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the commercialization of multiple blockbuster medicines including LIPITOR and CRESTOR.
Most recently, Adele Gulfo served as CEO for the Biopharma Commercial Unit at Sumitomo Pharma America, Inc., where she oversaw the commercial and development portfolio across various therapeutic areas, including oncology, rare disease, diabetes, urology, neurology, and women’s health. Before Sumitomo, she was CCBDO at Sumitovant Biopharma until its integration into Sumitomo Pharma America. Before joining Sumitovant, Ms. Gulfo served as CCDO at Roivant Sciences, where she played a key role in the formation of Sumitovant and led launch preparations for several major brands, such as ORGOVYX, GEMTESA, RETHYMIC, and MYFEMBREE. Earlier, Ms. Gulfo was the President and General Manager of Pfizer’s U.S. primary care business unit, which generated over $12 billion in revenue. At Pfizer, she was Senior Director and Launch Lead for LIPITOR®, which grew to a top-selling brand within two years of launch. Ms. Gulfo also served as the Country Manager for Pfizer’s U.S. biopharma business, which encompassed specialty and oncology business units. Before joining Pfizer, Ms. Gulfo held multiple VP positions at AstraZeneca, including leadership of Commercial Readiness, Business Development, and the Cardiovascular Business Unit, where she successfully led the launch and growth of CRESTOR into a multi-billion-dollar brand.
In addition to her executive roles, Ms. Gulfo currently serves on the Board of Directors of Tyra Biosciences, a publicly traded biotechnology company, and Enpro, a publicly traded industrial technology firm. She is also a member of the Innovation Growth Board at Mass General Brigham, the largest hospital-based research enterprise in the United States. Ms. Gulfo holds a B.S. in Biology from Seton Hall University and an MBA in Marketing, with highest honors, from Fairleigh Dickinson University.
About NewAmsterdam
NewAmsterdam Pharma is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated, and convenient LDL-C lowering therapy. In multiple Phase 3 trials, NewAmsterdam has investigated obicetrapib, an oral, low-dose, once-daily, highly selective cholesterol ester transfer protein inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
For more information: https://www.newamsterdampharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.